Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 36 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab for resected non-small cell lung cancer - adjuvant	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Atezolizumab for previously untreated recurrent or advanced non-small cell lung cancer unsuitable for platinum-doublet chemotherapy	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Atezolizumab for muscle-invasive urothelial carcinoma –adjuvant	Atezolizumab (Tecentriq; MPDL3280A)	Bladder cancer	Urological Cancer	2019	View \| Download
Atezolizumab for adjuvant treatment of squamous cell carcinoma of the head and neck	Atezolizumab (Tecentriq; MPDL3280A)	Head and neck cancer	Head and Neck Cancer	2021	View \| Download
Atezolizumab adjuvant therapy for treating renal cell carcinoma in people at high risk of developing metastasis following nephrectomy	Atezolizumab (Tecentriq; MPDL3280A)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line	Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2017	View \| Download